{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:55:31Z","timestamp":1793156131880,"version":"4.5.0"},"reference-count":64,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Malignant glioma, the most lethal form of brain cancer, presents with an immunosuppressive microenvironment that obstructs tumor cell clearance and hampers immunotherapeutic interventions. Despite advancements in characterizing cellular and extracellular profiles in cancer, the immunosuppressive mechanisms specific to glioma remain poorly understood. We conducted single-cell RNA sequencing of glioma samples, which revealed a select subset of human and mouse glioma cells that express CD83, a marker associated with mature antigen-presenting cells. To investigate the impact of tumor cell CD83 expression on glioma outcomes, we used an immunocompetent mouse model of glioma, bioinformatic analyses of human samples, and in vitro assays. Our findings revealed that CD83+ tumor cells contribute to tumor growth suppression and are associated with enhanced cytotoxic T-cell profiles and activated CD8+ T cells. Increased proinflammatory cytokines were identified in CD83-overexpressing tumor conditions, which were also correlated with long-term CD8+ antitumor responses. Importantly, tumor-derived CD83 could mediate communication with T cells, altering the immune microenvironment to potentially enhance immune-related tumor clearance. Collectively, our data suggest that tumor cell expression of CD83 supports the endogenous antitumor T-cell constituency in malignant glioma. Future research endeavors may aim to further investigate whether CD83 expression can enhance immunotherapeutic approaches and improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Immunosuppression in malignant glioma remains a barrier to therapeutic development. CD83 overexpression in human and mouse glioma increases survival. CD83+ tumor cells promote signatures related to cytotoxic T cells, enhanced activation of CD8+ T cells, and increased proinflammatory cytokines. These findings suggest that tumor-expressed CD83 could mediate tumor\u2013immune communications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0281","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T09:21:44Z","timestamp":1732699304000},"page":"3209-3223","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor Expression of CD83 Reduces Glioma Progression and Is Associated with Reduced Immunosuppression"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2627-9754","authenticated-orcid":false,"given":"Malcolm F.","family":"McDonald","sequence":"first","affiliation":[{"name":"1Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas."},{"name":"2Development, Disease Models, and Therapeutics, Baylor College of Medicine, Houston, Texas."},{"name":"3Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2793-2022","authenticated-orcid":false,"given":"Rachel Naomi","family":"Curry","sequence":"additional","affiliation":[{"name":"3Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4054-9740","authenticated-orcid":false,"given":"Isabella","family":"O\u2019Reilly","sequence":"additional","affiliation":[{"name":"3Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6876-8479","authenticated-orcid":false,"given":"Brittney","family":"Lozzi","sequence":"additional","affiliation":[{"name":"3Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1187-6939","authenticated-orcid":false,"given":"Alexis","family":"Cervantes","sequence":"additional","affiliation":[{"name":"3Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-3179","authenticated-orcid":false,"given":"Zhung-Fu","family":"Lee","sequence":"additional","affiliation":[{"name":"2Development, Disease Models, and Therapeutics, Baylor College of Medicine, Houston, Texas."},{"name":"3Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0678-8535","authenticated-orcid":false,"given":"Anna","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"3Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0356-3995","authenticated-orcid":false,"given":"Peihao","family":"He","sequence":"additional","affiliation":[{"name":"3Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0261-0406","authenticated-orcid":false,"given":"Carrie","family":"Mohila","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Texas Children\u2019s Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9696-1118","authenticated-orcid":false,"given":"Arif O.","family":"Harmanci","sequence":"additional","affiliation":[{"name":"5School of Biomedical Informatics, University of Texas Health Science Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-9041","authenticated-orcid":false,"given":"Akdes","family":"Serin Harmanci","sequence":"additional","affiliation":[{"name":"6Center for Cancer Neuroscience, Baylor College of Medicine, Houston, Texas."},{"name":"7Department of Neurosurgery, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6335-1081","authenticated-orcid":false,"given":"Benjamin","family":"Deneen","sequence":"additional","affiliation":[{"name":"2Development, Disease Models, and Therapeutics, Baylor College of Medicine, Houston, Texas."},{"name":"6Center for Cancer Neuroscience, Baylor College of Medicine, Houston, Texas."},{"name":"7Department of Neurosurgery, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3609-3491","authenticated-orcid":false,"given":"Ganesh","family":"Rao","sequence":"additional","affiliation":[{"name":"6Center for Cancer Neuroscience, Baylor College of Medicine, Houston, Texas."},{"name":"7Department of Neurosurgery, Baylor College of Medicine, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"2025051308432636700_bib1","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.3390\/cancers14164023","article-title":"Next steps for immunotherapy in glioblastoma","volume":"14","author":"Cao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025051308432636700_bib2","doi-asserted-by":"crossref","first-page":"e163446","DOI":"10.1172\/JCI163446","article-title":"Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy","volume":"133","author":"Khan","year":"2023","journal-title":"J Clin Invest"},{"key":"2025051308432636700_bib3","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1158\/1078-0432.CCR-12-2130","article-title":"IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival","volume":"18","author":"Wainwright","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025051308432636700_bib4","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00401-011-0858-3","article-title":"Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression","volume":"122","author":"Mittelbronn","year":"2011","journal-title":"Acta Neuropathol"},{"key":"2025051308432636700_bib5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/neuonc\/nos014","article-title":"Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy","volume":"14","author":"Crane","year":"2012","journal-title":"Neuro Oncol"},{"key":"2025051308432636700_bib6","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1158\/1078-0432.CCR-12-3314","article-title":"Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages","volume":"19","author":"Bloch","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2025051308432636700_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","article-title":"Immune suppression in gliomas","volume":"151","author":"Grabowski","year":"2021","journal-title":"J Neurooncol"},{"key":"2025051308432636700_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro Oncol"},{"key":"2025051308432636700_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jneuroim.2006.03.006","article-title":"T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy","volume":"175","author":"Walker","year":"2006","journal-title":"J Neuroimmunol"},{"key":"2025051308432636700_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3171\/jns.1987.67.2.0231","article-title":"Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas","volume":"67","author":"Elliott","year":"1987","journal-title":"J Neurosurg"},{"key":"2025051308432636700_bib11","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1158\/1078-0432.CCR-17-1846","article-title":"T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025051308432636700_bib12","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"2025051308432636700_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"2025051308432636700_bib14","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025051308432636700_bib15","doi-asserted-by":"crossref","first-page":"e163447","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J Clin Invest"},{"key":"2025051308432636700_bib16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025051308432636700_bib17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025051308432636700_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"2025051308432636700_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.semcancer.2007.06.008","article-title":"Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors","volume":"17","author":"Mescher","year":"2007","journal-title":"Semin Cancer Biol"},{"key":"2025051308432636700_bib20","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"2025051308432636700_bib21","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2012.02.006","article-title":"The three main stumbling blocks for anticancer T cells","volume":"33","author":"Baitsch","year":"2012","journal-title":"Trends Immunol"},{"key":"2025051308432636700_bib22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"2025051308432636700_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2025051308432636700_bib24","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025051308432636700_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","article-title":"Actively personalized vaccination trial for newly diagnosed glioblastoma","volume":"565","author":"Hilf","year":"2019","journal-title":"Nature"},{"key":"2025051308432636700_bib26","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1073\/pnas.0400880101","article-title":"Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137","volume":"101","author":"Yang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025051308432636700_bib27","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1073\/pnas.071477498","article-title":"Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells","volume":"98","author":"MacAry","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025051308432636700_bib28","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2005-05-2073","article-title":"Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity","volume":"107","author":"Hirano","year":"2006","journal-title":"Blood"},{"key":"2025051308432636700_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.neuron.2023.01.013","article-title":"Glioma epileptiform activity and progression are driven by IGSF3-mediated potassium dysregulation","volume":"111","author":"Curry","year":"2023","journal-title":"Neuron"},{"key":"2025051308432636700_bib30","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"key":"2025051308432636700_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41586-021-03465-8","article-title":"Comparative cellular analysis of motor cortex in human, marmoset and mouse","volume":"598","author":"Bakken","year":"2021","journal-title":"Nature"},{"key":"2025051308432636700_bib32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"2025051308432636700_bib33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.32614\/RJ-2016-021","article-title":"Mclust 5: clustering, classification and density estimation using Gaussian finite mixture models","volume":"8","author":"Scrucca","year":"2016","journal-title":"RJ"},{"key":"2025051308432636700_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41467-019-13779-x","article-title":"CaSpER identifies and visualizes CNV events by integrative analysis of single-cell or bulk RNA-sequencing data","volume":"11","author":"Serin Harmanci","year":"2020","journal-title":"Nat Commun"},{"key":"2025051308432636700_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41587-022-01468-y","article-title":"Haplotype-aware analysis of somatic copy number variations from single-cell transcriptomes","volume":"41","author":"Gao","year":"2023","journal-title":"Nat Biotechnol"},{"key":"2025051308432636700_bib36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1186\/s12864-022-09004-7","article-title":"XCVATR: detection and characterization of variant impact on the Embeddings of single -cell and bulk RNA-sequencing samples","volume":"23","author":"Harmanci","year":"2022","journal-title":"BMC Genomics"},{"key":"2025051308432636700_bib37","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2025051308432636700_bib38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"2025051308432636700_bib39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"2025051308432636700_bib40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"2025051308432636700_bib41","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2025051308432636700_bib42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2025051308432636700_bib43","doi-asserted-by":"crossref","first-page":"e001408","DOI":"10.1136\/jitc-2020-001408","article-title":"Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review","volume":"8","author":"Lecoultre","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025051308432636700_bib44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"2025051308432636700_bib45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0008-8749(88)90109-8","article-title":"Effects of interferon-gamma on the activation of human T lymphocytes","volume":"111","author":"Siegel","year":"1988","journal-title":"Cell Immunol"},{"key":"2025051308432636700_bib46","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell"},{"key":"2025051308432636700_bib47","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","article-title":"Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes","volume":"181","author":"Friebel","year":"2020","journal-title":"Cell"},{"key":"2025051308432636700_bib48","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization","volume":"24","author":"Pombo Antunes","year":"2021","journal-title":"Nat Neurosci"},{"key":"2025051308432636700_bib49","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"key":"2025051308432636700_bib50","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025051308432636700_bib51","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/labinvest.3700233","article-title":"Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain","volume":"85","author":"Zagzag","year":"2005","journal-title":"Lab Invest"},{"key":"2025051308432636700_bib52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejca.2016.09.010","article-title":"Turning tumour cells into antigen presenting cells: the next step to improve cancer immunotherapy?","volume":"68","author":"de Charette","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025051308432636700_bib53","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s11060-011-0537-1","article-title":"Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma","volume":"104","author":"Bu","year":"2011","journal-title":"J Neurooncol"},{"key":"2025051308432636700_bib54","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/0008-5472.CAN-03-3505","article-title":"Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma","volume":"64","author":"Yu","year":"2004","journal-title":"Cancer Res"},{"key":"2025051308432636700_bib55","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-17-2769","article-title":"Immunotherapy of primary brain tumors: facts and hopes","volume":"24","author":"Buerki","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025051308432636700_bib56","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41416-022-01864-w","article-title":"Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them","volume":"127","author":"Habashy","year":"2022","journal-title":"Br J Cancer"},{"key":"2025051308432636700_bib57","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2025051308432636700_bib58","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025051308432636700_bib59","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","article-title":"T-cell dysfunction in glioblastoma: applying a new framework","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025051308432636700_bib60","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","article-title":"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau","year":"2018","journal-title":"J Transl Med"},{"key":"2025051308432636700_bib61","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"2025051308432636700_bib62","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.4049\/jimmunol.169.4.2003","article-title":"Complement receptor 3 (CD11b\/CD18) mediates type I and type II phagocytosis during nonopsonic and opsonic phagocytosis, respectively","volume":"169","author":"Le Cabec","year":"2002","journal-title":"J Immunol"},{"key":"2025051308432636700_bib63","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1126\/science.282.5394.1717","article-title":"Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases","volume":"282","author":"Caron","year":"1998","journal-title":"Science"},{"key":"2025051308432636700_bib64","doi-asserted-by":"crossref","first-page":"eaau9240","DOI":"10.1126\/scitranslmed.aau9240","article-title":"Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies","volume":"11","author":"Panni","year":"2019","journal-title":"Sci Transl Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0281\/3522910\/crc-24-0281.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/12\/3209\/3528955\/crc-24-0281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/12\/3209\/3528955\/crc-24-0281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:44:45Z","timestamp":1747125885000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/12\/3209\/750739\/Tumor-Expression-of-CD83-Reduces-Glioma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,1]]},"references-count":64,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0281","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29050155","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050161","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28107011","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727389","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28107008","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727377","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727383","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28107014","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727395","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28107002","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28106984","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28106996","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050149","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050146","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050152","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28106990","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28106999","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28107005","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727386","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727392","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28106981","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28106993","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29050158","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28106987","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7603514","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,1]]}}}